Justo Aznar Lucea-rekin lankidetzan egindako argitalpenak (10)

2004

  1. Homozygous deficiency of heparin cofactor II: Relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis

    Circulation, Vol. 110, Núm. 10, pp. 1303-1307

1996

  1. Quantification of circulating activated protein C in human plasma by immunoassays - Enzyme levels are proportional to total protein C levels

    Thrombosis and Haemostasis, Vol. 75, Núm. 1, pp. 56-61

1995

  1. Activation of the protein C pathway in acute sepsis

    Thrombosis Research, Vol. 79, Núm. 1, pp. 83-93

1993

  1. Complex formation between protein c inhibitor and tissue plasminogen activator during thrombolytic therapy. Evidence of activation of protein C pathway

    Fibrinolysis and Proteolysis, Vol. 7, Núm. 5, pp. 308-315

  2. Fibrinolytic changes during acute vascular damage induced by Mediterranean spotted fever

    Fibrinolysis and Proteolysis, Vol. 7, Núm. 5, pp. 324-329

  3. Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators

    Thrombosis Research, Vol. 70, Núm. 2, pp. 117-122

1992

  1. Activated protein C:α1-antitrypsin (APC:α1AT) complex as a marker for in vitro diagnosis of prethrombotic states

    Thrombosis Research, Vol. 66, Núm. 5, pp. 499-508

1991

  1. Evidence of activation of the protein C pathway during acute vascular damage induced by mediterranean spotted fever

    Blood, Vol. 78, Núm. 2, pp. 416-422

1990

  1. Protein C inhibitor and other components of the protein C pathway in patients with acute deep vein thrombosis during heparin treatment

    Thrombosis and Haemostasis, Vol. 63, Núm. 3, pp. 380-382

1989

  1. Incidence of increased plasminogen activator inhibitor in patients with deep venous thrombosis and/or pulmonary embolism

    Thrombosis Research, Vol. 56, Núm. 4, pp. 565-570